ClinicalTrials.gg
RecruitingNCT06451861Updated Nov 17, 2025

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

A Phase 2 interventional study of Chidamide and Venetoclax in Acute Myeloid Leukemia, sponsored by Guangdong Provincial People's Hospital. Recruiting at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Guangdong Provincial People's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing tucidinostat in Leukemia, Myeloid, Acute — 11 open to participants now, 11 under way, 1 of them phase 3. tucidinostat · Leukemia, Myeloid, Acute.

Planned enrollment
Largest of 14
240 · median 99
Started
2024
with 4 others
Phase 2
9 of 14
6 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
9th of 14
by date
Lead sponsor
2 of 14
Guangdong Provincial People's Hospital

Among the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, this one has the largest planned enrollment, is one of 5 that started in 2024, is one of 9 in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 9th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

11 of the 14 studies testing tucidinostat in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tucidinostat in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia

Read the detailed description

Acute myeloid leukemia (AML) is a clonal malignant blood disease with genetic heterogeneity and originated from hematopoietic stem progenitor cells.In the past 50 years, the "3+7" induction regimen represented by cytotoxic drugs (including anthracyclines/anthraquinones combined with cytarabine) has remained the standard induction regimen for newly diagnosed AML patients with intensive chemotherapy. In AML patients \<60 years old, the "3+7" regimen induces a complete response rate of 60% to 80%, but the treatment-related mortality is as high as 13%, and more than half of the patients face the threat of relapse, and the 5-year overall survival rate is about 35% to 40%.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • ABC-14 regimen
  • "3+7" regimen
  • AB-14 regimen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments);
  2. Age ≥18 years old;
  3. ≤4;
  4. The fertile woman agrees to use effective during the treatment period and up to 3 months after the end of the treatment; Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Known history of allergy to the drug;
  2. Resistance to azacytidine, azacitidine, Venetoclax;
  3. Inability to take oral medication;
  4. Combined with uncontrolled active infections (including bacterial, fungal or viral infections);
  5. Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc.;
  6. Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    ABC-14 regimen

    AZA,Venetoclax,Chidamide

    Drug: Chidamide · Drug: Venetoclax · Drug: azacitidine

  • Active comparator
    3+7 chemotherapy regimen

    Daunorubicin/idarubicin/mitoxantrone and cytarabine

    Drug: Anthracyclines or anthraquinones · Drug: cytarabine

  • Active comparator
    AB-14 regimen

    AZA,Venetoclax

    Drug: Venetoclax · Drug: azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Composite complete remission (CRc)

    composite complete remission,CRc: CR + CRi + MLFS

    Time frame: 2 months

Secondary outcomes

  1. the rate of MRD turn negative

    minimal residual disease turn negative

    Time frame: 6 months

  2. DoR

    Duration of remission

    Time frame: 2 year

  3. RFS

    Relapsed-free survival

    Time frame: 1 year

  4. OS

    Overall survival

    Time frame: 1 year

  5. AE

    Incidence of of grade 3-4 adverse events/Duration of severe myelosuppression/ Incidence of severe infection/Treatment-related mortality, according to Common Terminology Criteria for Adverse Events, versions 5.0

    Time frame: Throughout the study until the end, up to 2 years

07

Study locations

13 of 13 sites recruiting
  • Dongguan General Hosptial
    Dongguan, Guangdong, China
    Recruiting
    • yirong Jiang · Contact
  • Foshan First People's Hospital
    Foshan, Guangdong, China
    Recruiting
    • Ying Zhao · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
    Recruiting
    • Xin Du · Contact
    • Jianyu WENG · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
    Recruiting
    • yang Liang · Contact
  • The Fifth Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Runhui Zheng · Contact
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong, China
    Recruiting
    • xueyi Pan · Contact
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Zhenqian Huang · Contact
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
    Recruiting
    • Liye Zhong · Contact
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • xu Ye · Contact
  • Shenzhen second people's Hospital
    Shenzhen, Guangdong, China
    Recruiting
    • xin Du · Contact
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
    Recruiting
    • Yuming ZHANG · Contact
  • Zhuhai General Hosptial
    Zhuhai, Guangdong, China
    Recruiting
    • xiaoliang Li · Contact
  • Hainan General Hosptial
    Haikou, Hainan, China
    Recruiting
    • Li'e Lin · Contact
08

References and documents

Publications

  • Yan H, Huang X, Wu P, Deng C, Li M, Lai P, Du X, Weng J. Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. Trials. 2025 Dec 10;27(1):38. doi: 10.1186/s13063-025-09339-y. PubMed 41366419 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 28 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Jun 11, 2024
StartActual
Aug 21, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06451861
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Aug 21, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Jianyu Weng
Contact
wengjianyu@gdph.org.cn
020-83827812
Du Xin
Contact
xind@gdph.org.cn
020-83827812
Jianyu Weng
principal investigator · Guangdong Provincial People Hosptial

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Venetoclax · Azacitidine

Start the discussion